Last updated: February 16, 2026
What Is the Market Status of NDC 00054-0812?
NDC 00054-0812 corresponds to Ibrutinib, marketed under the brand name Imbruvica. Approved by the FDA in 2013, it is indicated for multiple hematological malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM). As of 2023, Ibrutinib remains a leading BTK inhibitor with a significant market share in its therapeutic indications.
How Is the Current Market for Ibrutinib Structured?
The Ibrutinib market is characterized by high brand dominance, with key competitors and biosimilars starting to enter in select indications. Major factors influencing market dynamics include patent protection, licensing agreements, and manufacturing exclusivities.
Market Size and Growth
In 2022, the global hematological cancer therapeutics market was valued at approximately USD 15 billion, with Ibrutinib accounting for roughly USD 7 billion of that figure. The compound annual growth rate (CAGR) for this sector is estimated at 8% through 2027.
Key Competitors and Biosimilar Entry
While Ibrutinib controls approximately 75% of treatment shares in its indications, AZN’s molecular competitor Acalabrutinib gained FDA approval in 2019, capturing about 7% of the market. Biosimilar development is ongoing, with several dossiers submitted in Europe and Asia, though none have yet received FDA approval.
Patent Landscape
Boehringer Ingelheim holds multiple patents protecting Ibrutinib formulations and production methods, which are valid until 2027-2029. Patent cliffs are imminent, leading to expected generic entry from 2028 onward in some jurisdictions.
What Are Price Trends and Projections for Ibrutinib?
Current Pricing Environment
In the United States, wholesale acquisition costs (WAC) for Ibrutinib are approximately USD 14,000 per month per patient, translating to annual costs near USD 168,000. Patient out-of-pocket expenses and insurance coverage influence actual costs, with commercial insurers often negotiating substantial discounts.
Price Movements and Cost-Effectiveness
Price stability has persisted since 2015, but recent negotiations have led to minor discounts (~5-10%). Cost-effectiveness analyses suggest that, considering survival benefits, the drug maintains favorable value, supporting sustained pricing.
Future Price Projections
Anticipated generic entry from 2028 could reduce prices by up to 70%, similar to other once-patented oncology drugs. Biosimilar and generic versions, if approved, are projected to enter the market at USD 4,000–6,000 per month, potentially leading to a total market volume decline for the originator.
Impact of Biosimilars and Generics
If biosimilars achieve FDA approval by 2028, they could capture 40-50% of the market within two years, significantly reducing brand revenues. Price competition is expected to drive down monthly costs to USD 3,000–4,000.
What Are Key Regulatory and Market Risks?
- Patent expiration from 2027-2029 could accelerate generic entry.
- Patent litigation or delays in biosimilar approvals may prolong high prices.
- Competition from Acalabrutinib and Zanubrutinib could limit revenue growth.
- Manufacturing disruptions or supply chain issues could impact availability and pricing.
Summary of Market Dynamics and Price Projections
| Year |
Estimated Market Size |
Projected Price (USD/month) |
Notes |
| 2023 |
USD 7 billion |
USD 14,000 |
Current peak dominance |
| 2024-2027 |
USD 7–8 billion |
Stable at USD 14,000 |
No new biosimilar entries yet |
| 2028* |
Market likely declines |
USD 4,000–6,000 |
Patent expiry; biosimilar entry anticipated |
| 2030 |
Market consolidates or shifts |
ND |
Biosimilar proliferation |
(*Projected based on patent expiration timelines and typical biosimilar adoption patterns.)
Key Takeaways
- Ibrutinib (NDC 00054-0812) remains a dominant treatment in hematological malignancies with stable high pricing.
- Market revenue peaked in 2022 and is expected to decline significantly after patent expiry, around 2028.
- Biosimilar and generic competitors are likely to reduce prices by 50-70%, prompting a sharp decline in originator revenues.
- Patent expirations, competition, and regulatory developments are the primary factors shaping future market size and pricing.
- Strategic positioning will depend on patent litigation, approval of biosimilars, and healthcare reimbursement policies.
FAQs
1. What is the primary driver behind Ibrutinib’s market share?
Its efficacy in treating multiple hematological cancers and lack of direct competition until biosimilars enter around 2028.
2. When are biosimilars expected to enter the U.S. market for Ibrutinib?
Potentially around 2028, following patent expiration and regulatory approval procedures.
3. How will biosimilars impact the drug’s price?
Biosimilars could lead to price reductions of approximately 50-70%, depending on market uptake and competition.
4. Are there ongoing patent litigations affecting Ibrutinib?
Existing patents are valid until 2027-2029; litigation could delay biosimilar entry or influence patent extensions.
5. What regional differences influence pricing and market potential?
Pricing is higher in the U.S. due to reimbursement policies, while Europe and Asia see lower prices and more rapid biosimilar adoption.
Sources:
[1] Evaluate Pharma. Hematological cancer therapeutics market report 2023.
[2] FDA drugs database. Imbruvica approval history.
[3] IQVIA. Market trends for oncology drugs in 2023.
[4] PatentScope. Patent status of Ibrutinib formulations.
[5] MarketLine. Oncology drug pipeline and biosimilar forecasts.
